<DOC>
	<DOCNO>NCT01166269</DOCNO>
	<brief_summary>The purpose study try new route specific immunotherapy ( SIT ) . The current treatment form SIT subcutaneously ( SCIT ) , long treatment 50 injection subcutaneously upper arm . The investigator believe additional effect allergen inject directly lymph node , since , allergen presentation happen . The trial perform Switzerland significant effect three injection grass-allergen lymph node ( Clinicaltrials.gov ; NCT00470457 ) . The investigator would like see happens dose double , patient receive 6 injection , amount allergen earlier study ( 1000 SQ-U ) . Also outcome measurement slightly different patient note symptom diary . The patient divide three group use allocation : 1 group 6 injection allergen 1 group 3 injection allergen 3 injection placebo 1 group 6 injection placebo . The trial double blind .</brief_summary>
	<brief_title>Study Asses Efficacy Intralymphatic Immunotherapy</brief_title>
	<detailed_description />
	<criteria>grass pollen allergy least 2 season positive skin prick test positive Specific IgE least 2 . ( CAP ) Signed informed consent female negative pregnancy test . age limit rhinoconjunctivitis year round . uncontrolled seasonal asthma patient treat steroid continuously betablockers . pregnancy breastfeed HIV , Hepatitis B+c , immunological disease . psychiatric disease treatment SCIT SLIT within last 5 year participation clinical trial within last 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>grass-pollen allergy</keyword>
</DOC>